BioMarin Pharmaceutical (NASDAQ:BMRN) Receives Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reissued their overweight rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) in a report issued on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $110.00 target price on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for BioMarin Pharmaceutical’s FY2024 earnings at $2.05 EPS. BMRN has been the topic […]
More Stories
Garner Asset Management Corp Has $2.41 Million Stake in QUALCOMM Incorporated (NASDAQ:QCOM)
Garner Asset Management Corp trimmed its holdings in QUALCOMM Incorporated (NASDAQ:QCOM – Free Report) by 0.8% in the third quarter,...
Capital Investment Counsel LLC Raises Stock Holdings in The Progressive Co. (NYSE:PGR)
Capital Investment Counsel LLC raised its position in shares of The Progressive Co. (NYSE:PGR – Free Report) by 3.2% in...
Baltimore Washington Financial Advisors Inc. Buys Shares of 1,029 AbbVie Inc. (NYSE:ABBV)
Baltimore Washington Financial Advisors Inc. purchased a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the...
Garner Asset Management Corp Trims Position in Alphabet Inc. (NASDAQ:GOOG)
Garner Asset Management Corp trimmed its holdings in Alphabet Inc. (NASDAQ:GOOG – Free Report) by 1.5% in the third quarter,...
Summit Trail Advisors LLC Grows Stock Position in Oracle Co. (NYSE:ORCL)
Summit Trail Advisors LLC grew its holdings in shares of Oracle Co. (NYSE:ORCL – Free Report) by 33.0% in the...
Von Berge Wealth Management Group LLC Has $230,000 Position in Mastercard Incorporated (NYSE:MA)
Von Berge Wealth Management Group LLC cut its stake in shares of Mastercard Incorporated (NYSE:MA – Free Report) by 7.6%...